Biogen Financial Statements (BIIB)
|
|
|
|
Report date
|
|
|
15.02.2023 |
31.12.2023 |
14.02.2024 |
12.02.2025 |
06.02.2026 |
|
29.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
10 173 |
9 836 |
9 836 |
9 676 |
9 811 |
|
9 857 |
|
Operating Income, bln rub |
|
|
2 889 |
1 297 |
2 097 |
2 490 |
1 878 |
|
1 542 |
|
EBITDA, bln rub |
? |
|
3 537 |
2 377 |
2 377 |
2 996 |
3 101 |
|
2 789 |
|
Net profit, bln rub |
? |
|
3 047 |
1 161 |
1 161 |
1 632 |
1 293 |
|
1 372 |
|
|
OCF, bln rub |
? |
|
1 384 |
1 547 |
1 547 |
2 876 |
2 205 |
|
2 591 |
|
CAPEX, bln rub |
? |
|
240.3 |
311.4 |
311.4 |
359.8 |
153.8 |
|
157.9 |
|
FCF, bln rub |
? |
|
1 144 |
1 236 |
1 236 |
2 516 |
2 051 |
|
2 623 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
5 006 |
5 205 |
5 205 |
4 875 |
5 036 |
|
5 335 |
|
Cost of production, bln rub |
|
|
2 278 |
2 533 |
2 533 |
2 310 |
2 897 |
|
2 980 |
|
R&D, bln rub |
|
|
2 597 |
2 462 |
2 703 |
2 489 |
1 955 |
|
1 982 |
|
Interest expenses, bln rub |
|
|
246.6 |
246.9 |
246.9 |
250.3 |
246.0 |
|
275.1 |
|
|
Assets, bln rub |
|
|
24 554 |
26 845 |
26 845 |
28 049 |
29 440 |
|
29 483 |
|
Net Assets, bln rub |
? |
|
13 398 |
14 799 |
14 799 |
16 716 |
18 257 |
|
18 652 |
|
Debt, bln rub |
|
|
6 614 |
7 338 |
7 338 |
6 630 |
6 948 |
|
6 562 |
|
Cash, bln rub |
|
|
4 893 |
1 050 |
1 050 |
2 375 |
3 816 |
|
4 283 |
|
Net debt, bln rub |
|
|
1 721 |
6 288 |
6 288 |
4 255 |
3 132 |
|
2 279 |
|
|
Ordinary share price, rub |
|
|
276.9 |
258.8 |
258.8 |
152.9 |
176.0 |
|
190.8 |
|
Number of ordinary shares, mln |
|
|
145.3 |
144.7 |
144.7 |
145.7 |
146.7 |
|
147.2 |
|
|
Market cap, bln rub |
|
|
40 236 |
37 444 |
37 444 |
22 280 |
25 818 |
|
28 085 |
|
EV, bln rub |
? |
|
41 958 |
43 732 |
43 732 |
26 536 |
28 950 |
|
30 364 |
|
Book value, bln rub |
|
|
5 799 |
217 |
217 |
546 |
2 587 |
|
3 110 |
|
|
EPS, rub |
? |
|
21.0 |
8.02 |
8.02 |
11.2 |
8.82 |
|
9.32 |
|
FCF/share, rub |
|
|
7.87 |
8.54 |
8.54 |
17.3 |
14.0 |
|
17.8 |
|
BV/share, rub |
|
|
39.9 |
1.50 |
1.50 |
3.75 |
17.6 |
|
21.1 |
|
|
EBITDA margin, % |
? |
|
34.8% |
24.2% |
24.2% |
31.0% |
31.6% |
|
28.3% |
|
Net margin, % |
? |
|
29.9% |
11.8% |
11.8% |
16.9% |
13.2% |
|
13.9% |
|
FCF yield, % |
? |
|
2.84% |
3.30% |
3.30% |
11.3% |
7.94% |
|
9.34% |
|
ROE, % |
? |
|
22.7% |
7.85% |
7.85% |
9.76% |
7.08% |
|
7.36% |
|
ROA, % |
? |
|
12.4% |
4.33% |
4.33% |
5.82% |
4.39% |
|
4.65% |
|
|
P/E |
? |
|
13.2 |
32.2 |
32.2 |
13.7 |
20.0 |
|
20.5 |
|
P/FCF |
|
|
35.2 |
30.3 |
30.3 |
8.86 |
12.6 |
|
10.7 |
|
P/S |
? |
|
3.96 |
3.81 |
3.81 |
2.30 |
2.63 |
|
2.85 |
|
P/BV |
? |
|
6.94 |
172.4 |
172.4 |
40.8 |
9.98 |
|
9.03 |
|
EV/EBITDA |
? |
|
11.9 |
18.4 |
18.4 |
8.86 |
9.34 |
|
10.9 |
|
Debt/EBITDA |
|
|
0.49 |
2.65 |
2.65 |
1.42 |
1.01 |
|
0.82 |
|
|
R&D/CAPEX, % |
|
|
1 081% |
790.6% |
867.9% |
691.6% |
1 271% |
|
1 255% |
|
|
CAPEX/Revenue, % |
|
|
2.36% |
3.17% |
3.17% |
3.72% |
1.57% |
|
1.60% |
|
| Biogen shareholders |
